AKTS logo

AKTS Aktis Oncology, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$16.10
-0.21 (-1.29%)

Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates …

Market Cap: $865.32Mwww.aktisoncology.com

Price

No data yet.

Social Signal Score

47
5d
—
30d
30
1 mentions
—
60d
53
3 mentions
—
90d
58
4 mentions
—
news: 4

Analyst Ratings

9 analysts
Buyconsensus
Strong Buy 0Buy 6Hold 3Sell 0Strong Sell 0
Avg price target$37.4+132.3%
Low $35Median $37High $40
Current Consensus

Revenue

$3.90M+318.54%
$933.0K$1.92M$2.91M$3.90M
Dec 2024Sep 2026

Analyst Estimates

FY2025
$-55.16
$-122.50–$-24.03
3 analysts
FY2026
$-1.91
$-1.98–$-1.83
7 analysts
FY2027
$-2.35
$-3.15–$-1.39
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Matthew Roden
Sector
Healthcare
Industry
Biotechnology
Employees
79
Beta
0.45
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
6.92
www.aktisoncology.com